Pathstone Holdings
RMD icon

Pathstone Holdings’s ResMed RMD Stock Holding History

Pathstone Holdings’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.91M Sell
14,797
-177
-1% -$36.7K 0.01% 908
2026
Q1 		$3.36M Buy
14,974
+198
+1% +$49.3K 0.01% 746
2025
Q4 		$3.56M Sell
14,776
-2,368
-14% -$606K 0.01% 717
2025
Q3 		$4.69M Buy
17,144
+159
+0.9% +$43.4K 0.02% 576
2025
Q2 		$4.38M Sell
16,985
-11,778
-41% -$2.81M 0.02% 593
2025
Q1 		$6.44M Buy
28,763
+9,533
+50% +$2.23M 0.03% 468
2024
Q4 		$4.4M Buy
19,230
+2,757
+17% +$664K 0.02% 589
2024
Q3 		$4.02M Sell
16,473
-468
-3% -$105K 0.02% 633
2024
Q2 		$3.24M Buy
16,941
+392
+2% +$79.5K 0.01% 698
2024
Q1 		$3.28M Buy
16,549
+4,814
+41% +$882K 0.02% 678
2023
Q4 		$2.02M Buy
+11,735
New +$1.8M 0.01% 736

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Pathstone Holdings's RMD Position: Q2 2026 in Review

Pathstone Holdings reduced its ResMed (RMD) stake by 1.2% in Q2 2026, selling an estimated $36.7K and leaving 14,797 shares worth $2.91M. The position accounts for 0.01% of the portfolio, ranked #908.

Pathstone Holdings first reported a position in RMD in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.44M in Q1 2025. 882 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Pathstone Holdings held 14,797 shares of ResMed worth $2.91M as of Q2 2026.
  • Pathstone Holdings sold 177 ResMed shares in Q2 2026, an estimated $36.7K.
  • ResMed made up 0.01% of Pathstone Holdings's portfolio in Q2 2026, its #908 holding.
  • Pathstone Holdings first reported a position in ResMed in Q4 2023 and has held it in 11 quarters since.
  • Pathstone Holdings's ResMed position peaked at $6.44M in Q1 2025.
  • 882 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Pathstone Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.